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Abstract

Author Manuscript

We report an efficient therapeutic modality for platinum resistant ovarian cancer based on siRNAmediated suppression of a multifunctional DJ-1 protein that is responsible for the proliferation,
growth, invasion, oxidative stress and overall survival of various cancers. The developed
therapeutic strategy can work alone or in concert with a low dose of the first line chemotherapeutic
agent cisplatin, to elicit a maximal therapeutic response. To achieve an efficient DJ-1 knockdown,
we constructed the polypropylenimine dendrimer-based nanoplatform targeted to LHRH receptors
overexpressed on ovarian cancer cells. The quantitative PCR and western immunoblotting
analysis, revealed that the delivered DJ-1 siRNA downregulated the expression of targeted mRNA
and corresponding protein by more than 80% in various ovarian cancer cells. It was further
demonstrated that siRNA-mediated DJ-1 suppression dramatically impaired proliferation, viability
and migration of the employed ovarian cancer cells. Finally, the combinatorial approach led to the
most pronounced therapeutic response in all the studied cell lines, outperforming both siRNAmediated DJ-1 knockdown and cisplatin treatment alone. It is noteworthy that the platinumresistant cancer cells (A2780/CDDP) with the highest basal level of DJ-1 protein are most
susceptible to the developed therapy and this susceptibility declines with decreasing basal levels of
DJ-1. Finally, we interrogate the molecular underpinnings of the DJ-1 knockdown effects in the
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treatment of the ovarian cancer cells. By using various experimental techniques, it was revealed
that DJ-1 depletion: (1) decreases the activity of the Akt pathway, thereby reducing cellular
proliferation, migration and increasing the antiproliferative effect of cisplatin on ovarian cancer
cells; (2) enhances the activity of p53 tumor suppressor protein therefore restoring cell cycle arrest
functionality and upregulating the Bax-caspase pathway, triggering cell death; and (3) weakens the
cellular defense mechanisms against inherited oxidative stress thereby increasing toxic
intracellular radicals and amplifying the reactive oxygen species created by the administration of
cisplatin.

Graphical Abstract

Author Manuscript
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Ovarian cancer kills over 14,000 women every year in the United States alone and is known
as the “silent killer” due to the fact that very few symptoms are present until the later stages
of the disease’s development.1 Treatment options for advanced stage ovarian cancer are
limited and consist primarily of maximal debulking surgery followed by chemotherapy.2 The
main problem of cytoreductive surgery is related to the fact that it cannot provide complete
cancer resection and the need to administer chemotherapy post-surgery is of the utmost
importance to reduce ovarian cancer recurrence.3, 4 A combined chemotherapy regimen,
which involves two or more chemotherapeutic drugs such as platinum- or taxane-based
agents, has been shown to be most beneficial when treating ovarian cancer, as it targets
multiple cancer progression pathways.5, 6 The efficacy of conventional chemotherapy,
however, is limited by the aggressive nature of the ovarian cancer cells as well as their
ability to upregulate specific proteins responsible for multidrug resistance.7 Moreover, a
drawback of the current combinatorial chemotherapy is an increase of systemic side effects
when several drugs are added to the regimen.6 The adverse side effects in healthy organs
invariably impose dose reduction of chemotherapeutic drugs or even discontinuance of
therapy. Hence, there is a need to develop a novel therapeutic approach that can work alone
or in concert with a low dose of a single chemotherapeutic drug to elicit a maximal
therapeutic response while minimizing the risk of physically detrimental side effects.
Recently DJ-1, also known as PARK7, has been identified as an oncogenic driver and a
significant amount of experimental evidences has indicated that it is frequently
Mol Pharm. Author manuscript; available in PMC 2017 March 01.
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overexpressed in various human cancers, including prostate cancer, non-small cell lung
carcinoma, pancreatic ductal adenocarcinoma, and ovarian carcinoma.8, 9 It has been also
demonstrated that higher DJ-1 expression is positively associated with decreased survival in
patients with various tumor types including non-small cell lung cancer, esophageal
squamous cell carcinoma and ovarian cancer.10–12 DJ-1 is a multifaceted protein and to date
it has been found to be responsible for the proliferation, growth, invasion, and overall
survival of various cancers.9 DJ-1 is known to affect several cellular processes that drive
cancer progression (Figure 1). These processes include: (1) Proliferation, where DJ-1
inhibits the actions of phosphatase and tensin homolog (PTEN) allowing the Akt
proliferation pathway to proceed forward unchecked (Figure 1A);9, 13, 14 (2) Apoptosis and
cell cycle arrest, wherein DJ-1 binds to tumor protein p53 and inhibits its translocation to the
nucleus, thereby preventing enhanced expression of various anti-apoptotic proteins, as well
as p53’s ability to arrest cell cycle progression (Figure 1B);9, 15 (3) Oxidative stress
responses, DJ-1 can directly scavenge reactive oxygen species (ROS), as well as enhance
synthesis of reduced glutathione (GSH), and influence the destabilization of the NRF2/
Keap1 complex, thus allowing transcriptional factor NRF2 to accumulate in the nucleus, and
upregulate expression of multiple antioxidant proteins (Figure 1C). 16, 17 Additionally, DJ-1
has been identified as a cisplatin (CDDP) resistant biomarker in both non-small cell lung
cancer and pancreatic cancer, making DJ-1 a potentially important therapeutic target for the
treatment of DJ-1 overexpressing platinum resistant ovarian cancer.1812 Finally, several
studies reported that an increase in cytosolic DJ-1 is negatively correlated with overall
ovarian cancer cell survival.9, 10
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Based on the aforementioned facts, it has been hypothesized that siRNA-mediated silencing
of DJ-1 protein in combination with CDDP as a first line chemotherapeutic agent, 19 can
result in enhanced therapeutic efficacy for ovarian cancer while minimizing adverse side
effects. To verify the proposed hypothesis and achieve an efficient and targeted delivery of
DJ-1 siRNA to various ovarian cancer cells, we constructed a nanoparticle-based siRNA
delivery system, which contains four components (Figure 2): (1) siRNA molecules to
attenuate DJ-1 gene expression; (2) Polypropylenimine (PPI) dendrimer to act as a siRNA
carrier; (3) polyethylene glycol (PEG) to enhance stability and biocompatibility of the
nanoplatform; and (4) LHRH peptide, serving as a specific targeting moiety to ovarian
cancer cells.20 By incorporating the prepared siRNA nanoplatform (siRNA-NP) and the first
line chemotherapeutic agent CDDP, we have developed an efficient combinatorial
therapeutic approach for the treatment of platinum-resistant ovarian cancer cells and
elucidate the underlying role of the DJ-1 protein in ovarian cancer cells survival and growth.
Herein, we provide evidence for the abrogation of the platinum resistant phenotype of
several ovarian cancer cell lines via the suppression of DJ-1 protein. Our report relies on
three major observations: DJ-1 depletion (1) decreases the activity of the Akt pathway,
thereby reducing cellular proliferation, migration, and increasing the antiproliferative effect
of CDDP on ovarian cancer cells; (2) enhances the activity of p53 tumor suppressor protein
therefore restoring cell cycle arrest functionality and upregulating the Bax-caspase pathway,
triggering cell death; (3) weakens cellular ROS defense mechanisms thereby increasing toxic
intracellular radicals and amplifying the ROS created by the administration of CDDP.
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Human ovarian carcinoma A2780/CDDP, ES2, IGROV1 and SKOV3 cell lines were
purchased form ATCC (Manassas, VA). Generation 4 poly(propylene imine) dendrimer
(PPIG4) was obtained from SyMO-Chem (The Netherlands). Luteinizing Hormone
Releasing Hormone (LHRH) peptide (Gln-His-Trp-Ser-Tyr-DLys(DCys)-Leu-Arg-Pro-NHEt) was purchased from Amersham Peptide Co. (Sunnyvale, CA). α-Maleimide-ω-Nhydroxysuccinimide ester poly(ethylene glycol) (MAL-PEG-NHS 5 kDa) was acquired from
NOF Corporation (White Plains, NY). 2,4,6-Trinitrobenzene Sulfonic Acid (TNBS) assay
was purchased from Thermo Scientific (Waltham, MA). DJ-1 Stealth siRNA and Vybrant
Dye Cycle Green were purchased from Life Technologies (Grand Island, NY). siGLO Red
Transfection Indicator was obtained from GE Dharmacon (Lafayette, CO). Roswell Park
Memorial Institute (RPMI) media and Dulbecco’s Phosphate Buffered Saline (DPBS) were
acquired from Mediatech (Manassas, VA). Calcein AM cell viability assay and GSH-Glo
assay kits were purchased from Enzo Life Sciences (Farmingdale, NY). 10% pre-cast TrisGlycine acrylamide gels and Trans-Blot Turbo packs were obtained from Bio-Rad
(Hercules, CA). Peroxy Yellow 1 (PY1) was purchased from Sigma-Aldrich (St. Louis,
MO). All other chemicals and supplies were obtained through VWR International (Radnor,
PA).
Methods

Author Manuscript

Synthesis and characterization of the nanoplatform for siRNA delivery—PPIG4
dendrimer-based nanoplatform loaded with siRNA (siRNA-NP) was constructed according
to the previously described procedure.21–23 Synthesis of the siRNA-NP was initiated by
mixing DJ-1 siRNA (10 μM) with the PPIG4 at a nitrogen to phosphate (N/P) ratio of 4 in
MilliQ water and vortexing the reaction mixture for 1 h at room temperature. Afterwards,
MAL-PEG-NHS was added to the reaction mixture (NHS : NH2 = 1 : 5 molar ratio) and the
solution was vortexed during 1 h at room temperature. Finally, the LHRH peptide was
introduced to the solution (MAL-PEG-NHS : LHRH = 1 : 5 molar ratio) and the reaction
mixture was incubated for 12 h at room temperature. The complexation efficiency of siRNA
with PPIG4 was validated via gel retardation assay as previously described.22–26 Surface
modification of siRNA-PPIG4 complexes with PEG and LHRH peptide was confirmed by
using TNBS and the bicinchoninic acid assay (BCA) assays according to the previously
reported procedures.23, 27 The hydrodynamic diameter and zeta potential of the developed
nanoplatform were evaluated by employing dynamic light scattering (Malvern ZetaSizer
NanoSeries, Malvern, U.K.) as previously described.28

Author Manuscript

Cell Culture—A2780/CDDP, ES2, IGROV1, SKOV3 human ovarian carcinoma cells were
cultured using RPMI culture media supplemented with 10% FBS and 1% streptomycin/
ampicillin. Cells were grown at 37 °C in a humidified atmosphere of 5% CO2 (v/v) in
air.28–30
Cellular internalization of the siRNA-NP—Flow cytometry was employed to evaluate
cellular internalization efficiency of the siRNA-NP.27, 29 Briefly all cells were seeded in a
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six well cell culture plate at a density of 3 × 105 cells per well in RPMI media and allowed
to adhere to the plate overnight. Then, the prepared nanoplatform loaded with Dy-547
labeled siRNA, was added to the cells (siRNA = 1 μM) and incubated for 24 h prior to flow
cytometry analysis. The cells were trypsinized, collected in 0.5 mL Eppendorf tubes, washed
3 times with DPBS, resuspended in 200 μL DPBS, and analyzed using an Accuri C6 flow
cytometer (BD Biosciences, San Jose, CA). All data analyses were performed using the BD
C6 Accuri software. For the quantification of siRNA internalization via flow cytometry no
gating was used. Before the cellular uptake analysis non-treated cells were evaluated and the
auto fluorescence was measured and recorded to be in the 103 fluorescence decade for all the
tested cell lines. Then the cells treated with the constructed nanoplatform were analyzed and
histograms were plotted. To determine the percentage of cells transfected with the dyelabeled siRNA we drew a line using the BD software at the 103 decade and then allowed the
software to calculate percent cells containing fluorescently labeled siRNA.

Author Manuscript

Calcein AM Cell Viability Assay—For all cell viability endpoint experiments a modified
Calcein AM assay was performed by following our previously published
protocol.21, 27, 29–31

Author Manuscript

Real Time Quantitative PCR (qPCR) analysis—qPCR was used to validate gene
expression in each cell model before and after treatment with the siRNA-NP (siRNA = 1
μM) for 24 h.21, 22 Briefly, total RNA was extracted from the treated cells using an RNeasy
extraction kit (Qiagen, Hilden, Germany) and RNA concentrations were determined using a
BioSpec-nano UV-Vis Spectrophotometer (Shimadzu, Columbia, MD). Reverse
transcription was carried out using High-Capacity cDNA Reverse Transcription Kit (Thermo
Scientific) according to manufacturer’s protocol. Following cDNA preparation 100 ng of
each sample was loaded into the 96 well qPCR plate at a final volume of 20 μL, using βactin as endogenous control. Taqman primers for all gene targets were used for cDNA
template amplification. The qPCR plate was read using a Applied Biosystems Step One Plus
qPCR system (Thermo Scientific) with an initial cycle step at 50°C for 2 min followed by 40
cycles of 95°C for 15 s then 60°C for 1 min. The Ct threshold values were automatically
determined by the software, and all samples were done in triplicate for statistical analysis.

Author Manuscript

Western Immunoblotting analysis—Western immunoblotting analysis was performed
to confirm intracellular protein levels in all studied cell lines before and after treatment with
the siRNA-NP.21 Briefly all cell lines were seeded in T-25 flask at a cell density of 20 × 105
and incubated overnight at 37°C. Afterward the media was removed and 3.6 mL of fresh
media along with 0.4 mL of DJ-1 siRNA-NP was added to each flask (total volume 4 mL;
final siRNA concentration = 1 μM). The cells were collected and analyzed at various time
points. The immunoblotting procedure was carried out via our previously published
protocol.21 The antibodies were purchased from Thermo Scientific (Waltham, MA) and
antibody dilutions used in each experiment are as follows: DJ-1 (1:1000), NRF2 (1μg/mL),
p53 (1:500), phosphoAkt (1μg/mL), and β-actin (1:5000). The western blot band
quantification analysis was performed using ImageJ software. Band intensities of the tested
proteins are expressed as the percentage of the β-actin band intensity, which was set to
100%.
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ROS and GSH measurements—PY-1 and Glo-GSH Glutathione (Promega, Madison,
WI) kit-based assays were employed to evaluate intracellular levels of hydrogen peroxide
(H2O2) and GSH respectively in all cell lines prior to and after treatment with the siRNANP. The PY-1 assay was performed as per our previously published procedure.21 For GSH
measurements, all cells were seeded at a density of 5 × 103 in a clear bottom opaque walled
96 well plate to increase signal intensity. Then the cells were treated with the siRNA-NP
(1μM) for 24 h, followed by the assaying procedure according to the manufacture protocol.
The luminescence was read and analyzed using a Biotek synergy HT plate reader and
software (Biotek, Winooski, VT).

Author Manuscript
Author Manuscript

Real time cellular proliferation study—Cellular proliferation was measured using the
xCELLigence real time proliferation platform (ACEA Biosciences, San Diego, CA).21 Prior
to the assay, the E-plates were coated with 50 μL of fibronectin (10μg/mL) (Sigma-Aldrich),
per manufacturer’s protocol, and left in the biosafety cabinet for 30 min. Subsequently, the
plates were aspirated and 100 μL of cell free media was added to each well, followed by a
30 min equilibration period in the bio safety cabinet. The plates were then loaded onto the
instrument and background measurements were recorded for each of them using the RTCA
Software 1.2. Next, cells were seeded in each plate at a cellular that it resulted in growth that
did not reach 100% confluency in a 96 h time period density (A2780/CDDP: 5,000 cells/
well; ES2: 2,500 cells/well; IGROV1: 5,000 cells/well) and placed back into the incubator to
adhere to the plate before analysis. Once the cells adhered to the plate, they were placed onto
the proliferation platform and the experiment was started. After 2 h, 10 μL of media was
removed from the wells assigned for DJ-1 siRNA treatment alone and combinatorial therapy.
Ten μL of 10 μM DJ-1 siRNA-NP solution were added to the remaining 90 μL of media in
each well, resulting in a total volume of 100 μL and a final DJ-1 siRNA concentration of 1
μM. Following a 24 h incubation period with the DJ-1 siRNA-NP, an additional 90 μL of
media was added to the wells assigned for CDDP treatment only and combinatorial therapy.
Then, 10 μL of the corresponding concentrations of CDDP was added to these wells to
achieve the required IC50 concentrations for each cell line (A780/CDDP = 23.6 μM, ES2 =
3.8 μM, and IGROV = 1.9 μM). The IC50 concentrations for each cell line were determined
by using xCELLigence real time proliferation platform in time dependent manner (Figure
S1). In case of the control and DJ-1 siRNA therapy only, 100 μL of media was added to the
corresponding wells. The plates were then monitored for 96 h and analyzed using RTCA
Software 1.2.

Author Manuscript

Migration Assay—Cell migration was evaluated using a modified wound healing assay.32
Briefly, A2780/CDDP, ES2, and IGROV1 cells were seeded in a 6-well plate at a density of
2.5 × 105 cells per well and allowed to reach ~85% confluency before treatment. Afterwards
the scratch was made in a cell monolayer using a 200μL pipette tip. Immediately after the
scratching, the cells were washed with DPBS to remove any cellular debris, followed by
addition of fresh media containing the nanoplatform loaded with DJ-1 siRNA (final
concentration 1μM) to the respective wells. After 24 h, CDDP was added to the
corresponding wells assigned for CDDP alone and combinatorial therapies at the following
concentrations (A780/CDDP = 23.6 μM, ES2 = 3.8 μM, and IGROV = 1.9 μM). Images of
the cells were taken at 0, 24, and 48 h after a scratch was made to monitor cellular
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movement and gap reduction. Wound widths after 0 and 48 h were measured and % wound
closure was calculated as follows:

where W0h and W48h are the wound widths before and 48 h after treatment.

Author Manuscript

Cell cycle analysis—All cell lines were seeded in 6 well cell culture plates at a density of
3 × 105 cells per well and allowed to incubate at 37°C in 5% CO2 overnight. The following
day the media was removed and 1.8 mL of media along with 0.2 mL of 10 μM DJ-1 siRNA
loaded in the nanoplatform was added to the wells assigned for DJ-1 siRNA only and
combinatorial therapies, followed by an incubation period of 24 h. After 24 h CDDP was
added to the wells assigned for CDDP and combinatorial treatments and incubated for
another 24 h. The next day the cells were trypsinized, collected in 1.5 mL Eppendorf tubes,
and washed 3 times with DPBS. After washing the cells Vybrant Dye Cycle Green was
added to each tube according to the manufacturer’s protocol and incubated for 2 h at 37°C in
5% CO2 before flow cytometry analysis. All data was analyzed using BD C6 Accuri
software.

Author Manuscript

Caspase assay—The caspase assay (Thermo Fisher, Brookfield, WI) was performed to
quantify caspase activity in the used cell lines after each treatment. All cell lines were
seeded at a density of 5 × 103 cells per well in a black opaque walled clear bottom 96 well
plate (Corning, Corning, NY) and incubated overnight at 37°C and 5% CO2. The following
day cells were treated with CDDP, siRNA-NP and combinatorial therapy as described above.
After treatment, cells were then labeled with 7.5 μM CellEvent™ Caspase-3/7 Green
Detection Reagent for 30 minutes at 37°C and fluorescence was measured using a multi-well
plate reader (Synergy HT, BioTek Instruments, Winooski, VT) with 485 nm excitation and
528 nm emission filters. Cells were also imaged with an EVOS FL Cell Imaging System
(Life Technologies, Grand Island, NY).
Statistical analysis—Data was analyzed using descriptive statistics, single-factor analysis
of variance (ANOVA), and presented as mean values ± standard deviation (SD) from three to
six independent measurements. The comparison among groups was performed by the
independent sample Student’s t test. The difference between variants was considered
significant at p < 0.05.

RESULTS AND DISCUSSION
Author Manuscript

Selection and Characterization of Ovarian Cancer Models
To evaluate the therapeutic effect of DJ-1 protein suppression alone or in combination with
CDDP for ovarian cancer treatment, three characteristically different human ovarian
carcinoma cell lines such as A2780/CDDP, ES2 and IGROV-1 of various origins,
phenotypes, growths rates and CDDP resistance levels were employed. The A2780/CDDP
human epithelial ovarian cancer cell line (doubling time = 25 h) is highly resistant to the
CDDP.33 On the contrary, the ES2 human clear cell adenocarcinoma cell line (doubling time
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= 19 h) exhibits low to moderate resistance to a number of chemotherapeutic drugs including
CDDP.33 Finally, the IGROV1 human ovarian carcinoma cell line of the mixed origin
(doubling time = 27 h) is sensitive to CDDP.33, 34 To experimentally confirm the indicated
resistibility of the employed cancer cell lines to the CDDP, their real time proliferation
profiles, after incubation with various concentrations of the drug, were measured and the
IC50 values of 23.6 μM, 3.8 μM and 1.9 μM were obtained for A2780/CDDP, ES2 and
IGROV-1, respectively (Figure S1). According to qPCR and immunoblot analyses, all tested
ovarian cancer cell lines overexpress DJ-1 when compared to non-malignant HUVEC cells
(Figure 3A). The selection and use of HUVEC cells as a control was determined on the basis
that HUVEC cells are a non-cancerous cell line and they are of epithelial origin as well as
the tested ovarian cancer cells. HUVEC cells were employed as an intracellular base line of
the metabolic activities of a normally functioning cell. Moreover, the platinum-resistant
A2780/CDDP cells exhibited 1.8- and 2.4-fold increase in the basal level of DJ-1 mRNA as
compared to the platinum-sensitive ES2 and IGROV cells, respectively (Figure 3A). The
obtained results are in a good agreement with previous reports indicating that higher
expression levels of DJ-1 increase the chemoresistance of cancer cells by inhibiting various
apoptotic pathways.9, 18 For example, the proteomic studies performed by Zeng et al.
demonstrated that CDDP resistant lung cancer cells exhibited a 5.4-fold increase in basal
level of DJ-1 relative to their drug-sensitive counterparts.12
Preparation and Characterization of the Nanoplatform for DJ-1 siRNA Delivery to the
Ovarian Cancer Cells

Author Manuscript
Author Manuscript

siRNA delivery to the cancer cells is significantly hindered by a number of factors including
its nuclease degradation in serum and electrostatic repulsion by the negatively charged
cellular membrane.35 To facilitate intracellular siRNA delivery and achieve the efficient
suppression of DJ-1 mRNA, we constructed a dendrimer-based nanoplatform targeting the
ovarian cancer cells (Figure 2). Due to a high positively charged surface, the amineterminated PPIG4 dendrimers were able to effectively complex negatively charged siRNA
molecules through electrostatic interactions (Figure 3B).21, 22, 26 To minimize toxicity and
enhance biocompatibility, the positively-charged PPIG4-siRNA complexes (ζ = +23.03
± 2.22 mV) were modified with heterobifunctional PEG molecules by coupling NHS ester
groups of PEG to the primary amino groups of the dendrimers (Figure 2).21, 23, 29, 30 As a
result of this modification, the average zeta potential value of the PPIG4-siRNA complexes
decreased from +23.03 ± 2.22 mV to + 6.44 ± 2.14 mV indicating that the majority of
primary amine groups, which could cause cellular membrane damage, were successfully
PEGylated. The toxicity study validated that in comparison to non-modified PPIG4
complexes loaded with scrambled siRNA, the PEGylate complexes do not compromise
cellular viability (Figure 3C). Finally, to improve nanoplatform specificity to the ovarian
cancer cells, degradation-resistant LHRH peptide was attached to the distal end of PEG, by
coupling the maleimide group of PEG to cysteine thiol presented in the LHRH sequence
(Figure 2).21–23 The employed targeting moiety exploits preferential overexpression of
LHRH receptors on the extracellular surface of the various ovarian cancer cells, including
A2780/CDDP, ES2 and IGOV-1 cells.20–23, 36–41 Recently, we reported that gynecologic
(both primary and metastatic) tumors, obtained from patients with advanced ovarian
carcinoma, overexpressed LHRH receptors.42 Conversely, in the majority of healthy organs,
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there were no detectable levels of LHRH receptors.42 Moreover, our previous reports
confirmed that nanoplatforms equipped with LHRH peptide can efficiently deliver siRNA
molecules to LHRH-positive cancer cells both in vitro and in vivo.21–25 Following the
modification steps, we determined hydrodynamic size of the constructed siRNA
nanoplatform, which turned out to be 147.8 ± 11.0 nm (Figure 3D). The LHRH-targeted,
nanoplatform loaded with the scrambled siRNA, did not compromise viability (Figure 3C),
proliferation (Figure S2) and DJ-1 mRNA expression (Figure S3) of ovarian cancer cells,
indicating that the prepared siRNA delivery system is non-toxic.

Author Manuscript

To assess the cellular internalization efficiency of the LHRH-equipped nanoplatform and
investigate the role of LHRH peptide as a targeting ligand, LHRH receptor-positive (A2780/
CDDP, ES2 and IGROV1)39–41 and LHRH receptor-negative (SKOV3)39 ovarian cancer cell
lines were incubated with the delivery system containing fluorescently labeled siRNA for 24
h. According to the flow cytometry measurements, fluorescence signal was detected in more
than 85% A2780/CDDP, ES2 and IGROV1 cells, thus reflecting high internalization
efficiency of the nanoplatform into the LHRH receptor-positive ovarian cancer cell lines
(Figure 4). In contrast, only 50% LHRH receptor-negative SKOV3 cells were transfected
with the LHRH-targeted nanoplatform (Figure S4), indicating preferential uptake of the
constructed nanoplatform by the LHRH-positive cancer cells.

Author Manuscript

The qPCR analysis revealed that the 1μM DJ-1 siRNA delivered by the prepared
nanoplatform downregulated the expression of targeted mRNA to 22%, 15% and 14% of the
basal level in A2780/CDDP, ES2 and IGROV1 cells at 24 h post-transfection, respectively
(Figure 5A). In case of ES2 and IGROV1 cells, the suppression of DJ-1 mRNA levels
persisted 96 h following a single transfection. In contrast, the intracellular level of DJ-1
mRNA in the CDDP-resistant A2780 cells was gradually restored under the same
experimental conditions, recovering from the 22% after 24 h to 90% of the basal level at 96
h. This finding indicates that A2780/CDDP cells rely on DJ-1 protein for continued growth
and CDDP chemoresistance. The western immunoblotting analysis further confirmed the
similar trend in DJ-1 protein expression at the studied time points (Figure 5B). The
suppression of DJ-1 protein in both ES2 and IGROV1 cells remained persistent (<5% of the
basal level) at 96 h after a single transfection. Contrary to the qPCR data, the western blot
analysis revealed that the steady-state protein levels of DJ-1 in A2780/CDDP cells 24 h after
DJ-1 suppression were decreased to 11% of the basal DJ-1 protein concentrations, and after
96 h only recovered to 54%, indicating that the intracellular amount of DJ-1 protein
remained substantially suppressed at this time point. The discrepancy between mRNA and
protein levels is due to the finite amount of time between mRNA production and functional
protein assembly.

Author Manuscript

To achieve an efficient silencing of DJ-1 mRNA and the corresponding protein, 1 μM siRNA
therapeutic dose has been chosen based on the experimental observation. The qPCR data
revealed a dose dependent suppression of DJ-1 mRNA in the ovarian cancer cells 24 h after
transfection with the constructed nanoplatform containing various siRNA concentrations and
only 1 μM siRNA resulted in greater than 85% mRNA silencing (Figure S5). The selected
relatively high dose of DJ-1 siRNA is in a good agreement with a previously published
report, which indicated that complete suppression of DJ-1 mRNA was only achieved after
Mol Pharm. Author manuscript; available in PMC 2017 March 01.
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cells incubation for 36 h with 2 μM siRNA encapsulated in the commercially available
Oligofectamine.43 Our in vivo experiments further confirmed that DJ-1 siRNA (1.1 mg/kg)
delivered by the constructed nanoplatform after intravenous injection into mice bearing
subcutaneous ovarian cancer xenograft can substantially suppress the targeted DJ-1 protein
in cancer tissue (Figure S6). The employed siRNA dosage is in good agreement with the
previous clinical trials, which validated that administration of 1.5 mg/kg formulated siRNA
was well tolerated and has antitumor activity.44
Effect of DJ-1 Protein Suppression on Cancer Cells Proliferation, Viability and Migration

Author Manuscript

By measuring cell growth in real time with the xCELLigence System, it was demonstrated
that suppression of DJ-1 protein expression with siRNA, delivered by the constructed
nanoplatform, dramatically impaired proliferation of the employed ovarian cancer cells as
compared to the controls (Figure 6). It is worth mentioning that knockdown of DJ-1
expression by siRNA produced a superior reduction in ovarian cancer cell proliferation than
CDDP alone at the corresponding IC50 concentrations (Figure 6). Finally, the combinatorial
therapeutic approach led to the most pronounced inhibition of proliferation in all the studied
cell lines, outperforming both siRNA-mediated DJ-1 knockdown and CDDP treatment alone
(Figure 6). A decrease in cellular proliferation can be initially seen at ~48 h after the
addition of siRNA to the culture media in all cell lines. The observed effect is consistent
with the qPCR and western blot data (Figure 5), which validate the substantial suppression
of both DJ-1 mRNA and protein levels at the ~48 h time point. Furthermore, the inhibitory
effect of DJ-1 suppression on cell proliferation was most pronounced at 72 and 96 h posttreatment, where DJ-1 is predicted to have 3–4 half-lives of turn over, 45 achieving maximal
intracellular suppression.

Author Manuscript
Author Manuscript

In addition to the real-time proliferation studies, we also evaluated the effect of DJ-1
suppression alone or in combination with CDDP on the viability of cancer cells using
Calcein AM assay at 72 and 96 h post-transfection. As shown in Figure 7, siRNA-mediated
silencing of DJ-1 protein reduced viability of all the studied ovarian cancer cell lines. It is
noteworthy that the decrease in viability was the most pronounced in the CDDP-resistant
ovarian cancer cells (A2780/CDDP), which are characterized by the highest overexpression
of the DJ-1 protein (Figure 3A). In contrast, non-resistant IGROV cells, which exhibit the
lowest DJ-1 protein expression (Figure 3A), were found to be the least sensitive to the
siRNA treatment. Thus, viability of A2780/CDDP cells decreased from 100% to 32.3% 96 h
post-transfection relative to the control (Figure 7). In contrast, the viability of ES-2 ovarian
cancer cells with low resistance to CDDP and non-resistant IGROV-1 cells was 52.0 and
77.4% following the same treatment, respectively (Figure 7). Combination of DJ-1 siRNA
and CDDP lead to further decrease in cellular viability down to 14.3, 16.3 and 24.2% for
A2780/CDDP, ES-2, and IGROV-1 respectively. These results revealed that higher cellular
levels of DJ-1 could increase the survival of the ovarian cancer cells and enhance their
resistance to platinum-based chemotherapeutic drugs. Therefore, the siRNA-mediated
silencing of DJ-1 can efficiently inhibit both cancer cell survival and proliferation all the
while improving their sensitivity to chemotherapy. The obtained data is consistent with the
previous reports, which demonstrated that DJ-1 protein suppression in cancer cells can
effectively enhance the efficacy of the anti-cancer therapies.21, 46 For example, Zhang et al.

Mol Pharm. Author manuscript; available in PMC 2017 March 01.

Schumann et al.

Page 11

Author Manuscript

reported that the sensitivity of adriamycin resistance MCF-7 breast cancer cells to
chemotherapy was significantly improved following DJ-1 knockdown. In another study,
Schumann et al. demonstrated that the therapeutic efficacy of the photodynamic therapy for
ovarian cancer treatment was substantially enhanced through the siRNA-mediated inhibition
of the DJ-1 protein and this effect was more pronounced in A2780/AD cells than in ES2
cells, wherein former cells are characterized by higher basal levels of DJ-1 protein.21
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Because intracellular DJ-1 is known to regulate the process of cancer cell migration,47, 48 we
also employed the wound healing assay to assess an effect of siRNA-mediated DJ-1
knockdown alone or in combination with CDDP on the migration capacity of ovarian cancer
cells. Immediately after initiating an appropriate treatment, a scratch was made in the cell
monolayer and migration of cancer cells to the wound area was monitored at different time
points. In comparison to non-treated cells, cancer cells exposed to CDDP alone
demonstrated some decrease in migration (Figure 8). Furthermore, both DJ-1 suppression
alone and combinatorial therapy inhibited ovarian cancer cell motility. The obtained results
indicated that not only siRNA-induced DJ-1 suppression in combination with CDDP is
capable of a substantial reduction in ovarian cancer cell proliferation and viability, but it also
can suppress their migration and thus inhibit the potential metastasis development. These
results are in a good agreement with the previous studies reported by He et al., which
indicated that the cellular levels of DJ-1 correlate with migration and invasion of pancreatic
ductal adenocarcinoma cells and knockdown of DJ-1 expression can inhibit metastasis in
vivo.47 In another study, Pei et al. also reported that high expression of DJ-1 in
nasopharyngeal carcinoma enhances migratory properties of cancer cells in vitro and plays a
significant role in lymph node metastasis.48 Finally, Feng et al. reported that overexpression
of DJ-1 promotes migration of human glioma cells possibly through DJ-1-induced down
regulation of phosphatase PTEN.49
Role of the DJ-1 Protein Suppression in the Combinatorial Therapeutic Approach
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The observed superior anticancer effect of the combinatorial treatment is related to the fact
that the employed individual therapies can target multiple pathways that drive ovarian cancer
progression. It is established that CDDP halts the growth of ovarian carcinomas primarily
through the induction of DNA crosslinks and inhibition of cellular division.50 Unlike CDDP,
the siRNA-mediated DJ-1 silencing can concurrently affect several pathways that ovarian
cancer cells use for their proliferation, survival, migration and resistance to the
chemotherapeutic agents (Figure 1). We sought to interrogate molecular underpinnings of
the DJ-1 knockdown effects in the treatment of the ovarian cancer cells. Firstly, DJ-1 protein
plays a vital role in the proliferation and growth of cancer cells through direct mediation of
the Akt pathway.14, 51 It binds to PTEN thereby decreasing PTEN activity and increasing
phosphorylation of protein kinase Akt, thus promoting unregulated proliferation of cancer
cells (Figure 1A).9 Consequently, an increase in DJ-1 basal levels is associated with
enhanced aggressiveness of the cancer. For example, Wang et al. revealed that the
overexpression of DJ-1 in laryngeal squamous carcinoma cells is correlated with increased
expression of phosphorylated Akt (p-Akt) and the high intracellular levels of DJ-1 can
accelerate proliferation rate, increase the invasiveness and migration capacity, and reduce
apoptosis, by activating the PI3K/Akt/mTOR signaling axis.52 It has been confirmed that the
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proliferation rate of DJ-1-overexpressing SNU-46-D1 cells was faster than normal SNU-46
cells. Through the modulation of this signaling axis DJ-1 has also been implicated in tumor
growth and progression by upregulating hypoxia-inducible factor-1 (HIF1) protecting the
cells against hypoxia induced apoptosis. Vasseur et. al. reported a link between DJ-1 and
Akt, mTOR, and HIF1 activation as well as inhibition of p53-mediated cellular apoptosis in
tumor progression.53 In our study, immunoblot analysis validated that suppression of DJ-1
protein expression with siRNA delivered by the prepared nanoplatform, caused substantial
decrease in p-Akt levels in all the ovarian cancer cell lines tested (Figure 9A). Consequently,
the proliferation and viability of these cells was significantly decreased (Figures 6 and 7).
By analyzing perfusions and solid ovarian cancer tumors, Davidson et al. validated that DJ-1
is commonly expressed in advanced-stage ovarian carcinoma, but PTEN expression is
infrequent. It is assumed that DJ-1 expression could have a prognostic role in ovarian
carcinoma, possibly by suppressing the inhibitory action of PTEN on the Akt survival
pathway.10
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Second, DJ-1 could promote cancer cells survival, growth, and contributes, in part, to CDDP
resistance by repressing activity of p53 tumor suppressor protein.15, 54 The cytoprotective
function of DJ-1 is related to its ability to sequester p53, therefore inhibiting the apoptotic
p53-Bax-caspase pathway and cell cycle arrest functionality (Figure 1B).1555 The
aforementioned Akt signaling pathway is also influenced by the p53 protein activity.
Astanehe et al. reported that p53 binds to the promoter of PI3K and inhibits its actions,
preventing the phosphylation of Akt, thereby decreasing cell proliferation and growth.56
Using western blot analysis, we assessed a change of p53 protein level in the ovarian cancer
cells before and after treatment with the nanoplatform containing DJ-1 targeted siRNA. A
substantial increase in p53 protein expression was found in the all tested cancer cells
following siRNA treatment indicating inverse correlation between DJ-1 protein levels and
p53 expression (Figure 9B). To further validate the role of DJ-1 suppression in regaining p53
function and the subsequent negative impact on cells proliferation and viability, we assessed
caspase activity and cell cycle parameters of the cells in question before and after treatment
with DJ-1 siRNA-NP, CDDP or combinatorial therapy. The siRNA-mediated attenuation of
DJ-1 and the consequent increase in p53 expression resulted in blockade of cell cycle
progression at the G0/G1 phase (Figure 10). When compared to the untreated cells, the
G0/G1 population of siRNA-treated A2780/AD, ES2 and IGROV-1 cells increased by 43.6,
33.9, and 29.4%, respectively (Figure 10). This result suggests that the A2780/CDDP
ovarian cancer cells with the highest basal level of DJ-1 protein are most susceptible to the
DJ-1 siRNA-induced cell cycle arrest. Importantly, this susceptibility declines with
decreasing basal levels of DJ-1 as seen in ES2 and IGROV-1 cell lines. Finally, the
combinatorial therapy showed the most pronounced effect in blocking cell cycle progression
as compared to the standalone DJ-1 siRNA and CDDP treatments. The number of
A2780/AD, ES2 and IGROV-1 cells in the G0/G1 phase following combinatorial therapy
increased by 52.4, 40.6, and 37.4%, respectively when compared to the untreated cells. To
the best of our knowledge, this is the first report demonstrating that the knockdown of DJ-1
protein in ovarian cancer cells results in cell cycle arrest at the G0/G1 phase, which likely
contributes to the decrease in cell proliferation and viability. Previous studies showed that
certain anticancer agents such as curcumin and ellagic acid induced G0/G1 cell arrest
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through increased p53 levels and caused apoptosis in human bladder and breast cancer
cells.57, 58
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By using caspase assay, we also demonstrated that siRNA-mediated knockdown of DJ-1
protein substantially increased caspase activation in all the tested ovarian cancer cell lines in
comparison to the control and CDDP treatment alone (Figure 11A and S7). Our results are
in good agreement with the previous report, which indicated that DJ-1 blocks caspase-3
activation by repressing p53 function and therefore, decreasing the Bax protein level.15 It is
important to mention that the detected effect was the most pronounced in A2780/CDDP
cells characterized by the highest intracellular level of the DJ-1 protein. Thus, in comparison
to non-treated cells, incubation of A2780/CDDP, ES2 and IGROV1 cells with siRNA-NP
increased caspase activity by 75.6, 51.1, and 38.3%, respectively (Figure 11A). Finally,
combinatorial treatment resulted in further increase of caspase activation by 106.4, 84.9 and
83.6% in A2780/CDDP, ES2 and IGROV1 cells, respectively. The above results provided
evidence that siRNA-mediated DJ-1 silencing in ovarian cancer cells inhibits DJ-1 protective
function associated with its ability of repressing p53 transcriptional activity, therefore
inhibiting the apoptotic p53-Bax-caspase pathway and cell cycle arrest functionality.
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One of the main alterations in ovarian cancer cells, compared to nonmalignant ones, is
excessive cellular levels of toxic reactive oxygen species (ROS).59 The cancer cells have
developed a ROS defense system to protect themselves from intrinsic oxidative stress and to
provide resistance to ROS-induced therapies.60 Through multiple mechanisms, DJ-1 protein
plays an important role in protecting ovarian cancer cells from toxic intracellular ROS and
the exogenous ROS generated by various anticancer agents, including CDDP.61 Therefore,
weakening the cellular ROS defense mechanism by siRNA-mediated DJ-1 knockdown may
result in ROS-mediated cell death.
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DJ-1 has been shown to influence synthesis of the non-enzymatic antioxidant, reduced
glutathione (GSH), via upregulation of the rate limiting enzyme glutamate cysteine ligase
(GCL) thereby increasing intracellular GSH pool (Figure 1C).17 Godwin et al. reported that
ovarian cancer cells with a platinum resistant phenotype have increased intracellular GSH
concentration with a linear relationship to resistance.62 We also verified that platinumresistant A2780/CDDP cells have the highest basal levels of GSH when compared to the
ES2 and IGROV1 cells lines (Figure 11B). Following DJ-1 suppression, intracellular GSH
level is decreased by 56.4% in the A2780/CDDP cells where the ES2 and IGROV1 cells
were characterized by a 31.6% and 21.7% reduction, respectively (Figure 11B). These data
are in good agreement with the published hypothesis that GSH upregulation in platinumresistant cancer cells and the reliance of these cells on DJ-1 as a cellular GSH
mediator. 17, 62
Additionally, DJ-1 has been reported to directly influence the activity of the oxidative stressresponsive transcription factor NRF2, stabilizing it, therefore inhibiting its association with
the ubiquitinase Keap1 and increasing NRF2’s transcriptional activity.63–65 NRF2 plays a
critical role in redox regulation within the cell and is responsible for NRF2-regulated GSH
recycling via modulating the activity of glutathione reductase as well as transcriptional
regulation of a variety of other antioxidant stress response proteins (Figure 1C).16, 66, 67
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Using western blot analysis, we assessed NRF2 protein levels following siRNA-mediated
DJ-1 suppression and found a significant decrease in the amount of NRF2 protein in all the
tested cell lines, thus confirming DJ-1’s role in NRF2 stabilization (Figure 11C). Clements
et al. previously revealed that in the absence of intact DJ-1, NRF2 protein is unstable, and
transcriptional responses are consequentially decreased - both basally and after induction.63
Hence, the DJ-1/NRF2 functional axis presents a prospective therapeutic target in cancer
treatment and DJ-1 knockdown could contribute to ROS-mediated cell death.
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Finally, it has been reported that the redox-sensitive Cys-106 residue of DJ-1 is highly
susceptible to hydrogen peroxide (H2O2)-induced oxidation and may be responsible for
H2O2 scavenging.68 Consistently, DJ-1 has been shown to reduce or prevent H2O2-mediated
cell death.43 To evaluate the effect of DJ-1 suppression and CDDP on intracellular H2O2
levels, the employed cancer cell lines were subjected to the siRNA-loaded nanoplatform,
CDDP or combinatorial treatment. Following DJ-1 suppression, we observed an 81.0%
increase in intracellular H2O2 in the platinum resistant A2780/CDDP cells and a 63.4% and
46.2% increase in ES2 and IGROV1 cells, respectively (Figure 11D). This data is in
agreement with the basal levels of DJ-1 reported in this study, whereby higher levels of DJ-1
in the cells permit a more robust and efficient ROS scavenging.
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Similarly, CDDP has been shown to stimulate the production of endogenous ROS.69 To
understand the impact of CDDP on enhanced intracellular ROS generation, all cell lines in
question were treated at their respective IC50 concentrations. Following the treatment, these
cell lines exhibited small increase in ROS, ranging from a 2.02 to 12.32% relative to control
(Figure 11D). 69, 70 The elevated ROS seen with CDDP+DJ-1 suppression regimen was
greater than the increase in ROS seen in the sole DJ-1 suppression treatment group. Out of
all the cell lines the most pronounced ROS elevation occurred in the A2780/CDDP cell line,
where the difference between the DJ-1 suppression only and the combinatorial treatment
was 28.83% versus 11.36% and 8.45%, seen in the ES2, and IGROV-1 cell lines,
respectively (Figure 11D).
The above results revealed that upon DJ-1 suppression there is a reproducible substantial
increase in endogenous H2O2 as well as a significant decrease of intracellular GSH pool and
NRF2 protein. Such alteration in the intercellular ROS (produced as a consequence of a
weakened antioxidant defense system) further confirms the reliance of ovarian cancer cells
on DJ-1, which acts as a buffer for intracellular ROS. This data is in agreement with our
previously published observation of a dramatic increase in endogenous ROS in the DJ-1overexpressing A2780/AD (Adriamycin-resistant) cells upon the protein’s depletion in
combination with ROS-inducing photodynamic therapy.21
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CONCLUSIONS
A dendrimer-based, LHRH-targeted drug delivery system was constructed to deliver DJ-1
targeted siRNA to ovarian cancer cells in combination with CDDP. The DJ-1 nanoplatform
showed sufficient cellular uptake to achieve therapeutic DJ-1 mRNA suppression levels. The
silencing of DJ-1 provided a therapeutic approach that encompassed three ovarian cancer
survival pathways that intersect with CDDP’s mechanism of action: (i) increasing apoptosis;

Mol Pharm. Author manuscript; available in PMC 2017 March 01.

Schumann et al.

Page 15

Author Manuscript

(ii) decreasing cellular proliferation; and (iii) increasing intracellular ROS levels. In this
study, we found that DJ-1 suppression in combination with CDDP treatment is a feasible
therapeutic modality, and offers a new prospective avenue for the treatment of CDDPresistant ovarian cancer. The current work established a foundation for subsequent
evaluation of the developed combinatorial therapy in animal models with either
subcutaneous or orthotopic ovarian cancer tumors.
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Figure 1.
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Schematic illustration of the dendrimer-based nanoplatform for targeted delivery of DJ-1
siRNA to the ovarian cancer cells via LHRH receptor-mediated endocytosis and the role of
siRNA-induced suppression of DJ-1 protein in the combinatorial treatment. siRNA-mediated
knockdown prevents DJ-1 protein from (A) inhibiting the PTEN expression, thereby
promoting phosphorylation of Akt and activating cell proliferation and migration; (B)
suppressing p53 transcriptional activity, therefore inhibiting the apoptotic p53-Bax-caspase
pathway and cell cycle arrest functionality; (C) protecting cancer cells from intrinsic
oxidative stress and the consequent ROS-mediated apoptosis. DJ-1 facilitates GSH synthesis
via upregulation of the rate-limiting enzyme glutamate cysteine ligase (GCL). In addition,
DJ-1 stabilizes NRF2, which is responsible for both GSH recycling via modulating the
activity of glutathione reductase (GR) and transcriptional activation of various antioxidant
proteins.
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Figure 2.
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Schematic representation of the LHRH-targeted, PPIG4 dendrimer-based nanoplatform for
siRNA delivery. The developed nanoparticles contain four components: 1) DJ-1 siRNA, as
suppressors of the corresponding mRNA in the ovarian cancer cells; 2) PPIG4 dendrimers as
carriers for DJ-1 siRNA; 3) PEG, as an enhancer of nanoparticles stability and
biocompatibility and 4) LHRH peptide, as a targeting moiety to the ovarian cancer cells. The
approach for preparation of the nanoplatform consists of the following steps: 1)
Complexation of negatively charged DJ-1 siRNA by the positively charged PPIG4 into
nanometer-sized complexes via electrostatic interactions; 2) Modification of the PPIG4siRNA complexes with hydrophilic polymer by conjugation of PEG to PPIG4 amino groups
on the nanoplatform surface; (3) Conjugation of LHRH peptide to the distal end of PEG
layer through the maleimide (MAL) groups on the PEG and the thiol groups in LHRH
peptide. Due to the electrostatic interactions, the positively-charged dendrimer and
negatively-charged siRNA molecules spontaneously self-assemble into nanoparticles. An
excess of dendrimers results in encapsulation of siRNA molecules inside of the
nanoparticles and provides net positive charge on the nanoparticle surface, which in turn
protect the siRNA against serum nuclease degradation and facilitate cellular internalization.
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Figure 3.
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(A) Basal level of DJ-1 mRNA in non-malignant HUVEC and A2780/CDDP, ES2 and
IGROV1 ovarian cancer cells measured by quantitative PCR. The intracellular level of DJ-1
in HUVEC cells was used as a reference and set to 100%. Means ± SD are shown. *p < 0.05
when compared with HUVEC cells. Inset: Representative Western blot images of DJ-1
protein and β-Actin expression in HUVEC, A2780/CDDP, ES2 cells and IGROV1 cells. (B)
Representative agarose gel electrophoresis image of free siRNA (lane 1), PPIG4 (lane 2) and
siRNA incubated with PPIG4 at the following N/P (PPIG4 amine: siRNA phosphate groups)
ratios: 0.5 (lane 3), 1 (lane 4), 2 (lane 5), 4 (lane 6), 8 (lane 7) and 10 (lane 8). An efficient
binding of siRNA molecules with PPIG4 retards their gel electrophoretic mobility and
prevents siRNA staining by ethidium bromide (lanes 4–8) in comparison to free siRNA (lane
1). (C) Viability of A2780/CDDP cells after incubation for 48 h with (1) non-modified
PPIG4-siRNA complexes loaded with scrambled siRNA (1μM), (2) PPIG4-siRNA
complexes modified with PEG only and (3) PPIG4-siRNA complexes modified with both
PEG and LHRH peptide (siRNA-NP). Means ± SD are shown. *p < 0.05 when compared
with cancer cells treated with non-modified PPIG4-siRNA complexes. (D) Size distribution
profile of siRNA-NP evaluated by dynamic light scattering.
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Flow cytometry analysis validates high cellular internalization efficiency of LHRH-targeted
nanoplatform loaded with DY-547-labeled siRNA after incubation with (A) A2780/CDDP,
(B) ES2 and (C) IGROV1 ovarian cancer cells for 24 hours. The values on the right side of
the dashed line indicate percentage of cell population transfected with the fluorescent
siRNA.
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Figure 5.
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Quantitative PCR analysis (A) and band densitometry analysis of Western blots (B) reveal
expression of DJ-1 mRNA and corresponding protein levels in A2780/CDDP, ES2 and
IGROV1 ovarian cancer cells before (basal level) and after treatment with the DJ-1 siRNAloaded nanoplatform for 24 h. Band intensities of DJ-1 protein are expressed as the
percentage of the β-actin band intensity, which was set as 100%. Time point evaluation (24–
96 h) was performed to determine the duration of the siRNA silencing effect on DJ-1 levels
following a single transfection in all cell lines. Means ± SD are shown. *p < 0.05 when
compared with untreated cancer cells.
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Real time proliferation curves of A2780/CDDP, ES2 and IGROV1 ovarian cancer cells
treated with media (control), CDDP, DJ-1 siRNA-loaded nanoplatform and combinatorial
therapy. The DJ-1 siRNA-NP (siRNA = 1μM) and CDDP at the corresponding IC50
concentrations (A2780/CDDP = 23.6 μM, ES2 = 3.8 μM and IGROV1 = 1.9 μM) were
added to the appropriate wells 2 h and 24 h, respectively after the cells were seeded in the Eplate. In case of the combinatorial therapy, the siRNA-NP and CDDP were consequently
added to the assigned wells 2 h and 24 h, respectively after the cells were seeded in the Eplate.
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Viability of A2780/CDDP, ES2 and IGROV1 ovarian cancer cells after treatment with media
(control), DJ-1 siRNA-loaded nanoplatform and combinatorial therapy (Combo). Means ±
SD are shown. *p < 0.05 when compared with cancer cells treated with media.
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Figure 8.

A wound healing assay was employed to assess the migration of A2780/CDDP, ES2 and
IGROV1 cells exposed to media (control), CDDP, DJ-1 siRNA-NP and combinatorial
therapy within 48 h. White lines represents cellular migration border.
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Figure 9.
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The intracellular level of phosphorylated Akt (A) and p53 (B) proteins in A2780/CDDP, ES2
and IGROV1 cells before after treatment with DJ-1 siRNA-NP for 24 h. Expression of
proteins was evaluated by band densitometry analysis of Western blots from replicate
experiments. Band intensities of phosphorylated Akt and p53 proteins are expressed as the
percentage of the β-actin band intensity, which was set as 100%. Means ± SD are shown. *p
< 0.05 when compared with cancer cells treated with media. Representative Western blot
images of phosphorylated Akt, p53 and β-actin proteins expression in the ovarian cancer
cells before and after exposure to the DJ-1 siRNA treatment are provided.
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Figure 10.

Cell cycle alteration in A2780/CDDP, ES2 and IGROV1 ovarian cancer cells after treatment
with CDDP, DJ-1 siRNA-NP or combinatorial therapy. Top panel shows the results of flow
cytometry analysis using Vybrant® DyeCycle stain. Bottom panel depicts the percentage of
A2780/CDDP, ES2 and IGROV1 cells in G0/G1 phase of the cell cycle before and after
treatment with CDDP, DJ-1 siRNA-NP and combinatorial therapy.
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Figure 11.
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(A) The relative increase in caspase-3/7 activity in A2780/CDDP, ES2 and IGROV1 cells
before after treatment with CDDP, DJ-1 siRNA-NP and combinatorial therapy. The caspase
activity was set to 100%. (B) The relative intracellular level of reduced glutathione (GSH) in
ovarian cancer (A2780/CDDP, ES2 and IGROV1) cells before and after treatment with DJ-1
siRNA-NP for 24 h. The intracellular level of GSH in non-treated HEK293 cells was used as
a reference and set to 100%. (C) The intracellular level of NRF2 protein in A2780/CDDP,
ES2 and IGROV1 cells before after treatment with DJ-1 siRNA-NP for 24 h. Expression of
proteins was evaluated by band densitometry analysis of Western blots. Band intensities of
NRF2 protein in the various samples are expressed as the percentage of the β-actin band
intensity, which was set to 100%. Representative Western blot images of NRF2 proteins
expression in the ovarian cancer cells before and after exposure to the DJ-1 siRNA treatment
are provided. (D) Relative intracellular level of H2O2 in the ovarian cancer cells after
treatment with CDDP, DJ-1 siRNA-NP and combinatorial therapy. Cells incubated with
media were used as the control and intracellular level of H2O2 in these cells was set to
100%. Means ± SD are shown. *p < 0.05 when compared with cancer cells treated with
media.
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Figure S1. Representative IC50 curves for CDDP in A2780/CDDP, ES2 and IGROV1 ovarian
cancer cells obtained from the xCELLigence real time proliferation measurements. Each graph
consist of eight CDDP concentrations (A2780/CDDP = 100 – 0.8µM, ES2 and IGROV1 = 25 –
0.2µM) and were analyzed over a 96 h time period. The IC50 curves were calculated and plotted
using the xCELLigence software where a time dependent sigmoidal dose response curve was
generated for each cell line.
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Figure S2. Real time proliferation curves of A2780 ovarian cancer cells treated with media
(control), and nanoplatform loaded with scrambled siRNA.
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Figure S3. Level of DJ-1 mRNA in A2780/CDDP, ES2 and IGROV1 ovarian cancer cells
before (control) and after incubation for 24 h with the constructed nanoplatform containing 1 µM
scrambled siRNA.

Figure S4. Flow cytometry analysis demonstrates cellular internalization efficiency of LHRHtargeted nanoplatform loaded with DY-547-labeled siRNA after incubation with LHRH-negative
SKOV3 ovarian cancer cells for 24 h. The values on the right side of the red line indicate
percentage of cell population transfected with the fluorescent siRNA.
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Figure S5. Level of DJ-1 mRNA in ES2 and A2780/CDDP ovarian cancer cells before and after
incubation for 24 h with the constructed nanoplatform containing 0.25, 0.5, and 1.0 µM DJ-1
siRNA.

Figure S6. Expression of DJ-1 protein in tumor tissues. The nude mice bearing subcutaneous
xenografts of A2780 ovarian cancer cells were intravenously injected with saline (control) and
the nanoplatform loaded with DJ-1 siRNA (1.1 mg/kg). The harvested tumors were sectioned
and the sections were incubated with the primary DJ-1 antibody, following the incubation with
the green fluorescent dye–labeled secondary antibody. All slides were analyzed using EVOS
Cell Imaging fluorescent microscope.
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Figure S7. Microscopy images demonstrate caspase-3/7 activity (green fluorescence) in
A2780/CDDP, ES2 and IGROV1 cells before after treatment with CDDP, DJ-1 siRNA-NP and
combinatorial therapy.
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